Catalyst Wire Dossier Catalyst Wire Dossier

TPI-287

Drug timelines are a Plus or Pro feature.

12 regulatory and trial events tracked for TPI-287, covering 2007-10-15 to 2019-06-05. Get the full timeline:

Most recent: Clinical Trial Update: Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma [Phase 1, Phase 2]

See pricing